

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPROVAL FOR CLINICAL TRIAL OF GROUP'S PRODUCT TUL108 FOR INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the application for clinical trial of TUL108 for Injection, a Class 1 innovative drug self-developed by Zhuhai United Laboratories Co., Ltd., a wholly-owned subsidiary of the Company, was approved by China National Medical Products Administration with reference number CXHL2600206.

TUL108 for Injection is a novel, broad-spectrum β -lactamase inhibitor independently designed and developed by the Company. It is intended for the treatment of infections caused by Gram-negative or Gram-positive bacteria, including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), pulmonary infections and bloodstream infections. TUL108, in combination with meropenem, exhibits high susceptibility against carbapenem-resistant *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, providing full coverage for clinically urgent carbapenem-resistant Gram-negative bacteria.

The investigational new drug application for TUL108 for Injection has been approved by the United States Food and Drug Administration ("FDA") on 28 January 2026.

The development of TUL108 for Injection is expected to strengthen the Company's leading position in the anti-infective field. In the future, the Company will continue to dedicate itself to new product development, continuously enhancing its competitiveness and innovation capabilities in the pharmaceutical industry, and is expected to create more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 19 May 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.